OCGN logo

Ocugen, Inc. Common Stock

OCGN

OCGN: Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

more

Show OCGN Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recently reported changes by institutional investors

Quarterly net insider trading by OCGN's directors and management

Government lobbying spending instances

  • $30,000 Jul 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $30,000 Jul 19, 2023 Issue: Health Issues
  • $20,000 Apr 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $30,000 Apr 18, 2023 Issue: Health Issues
  • $105,000 Feb 23, 2023 Issue: Health Issues
  • $10,000 Jan 20, 2023 Issue: Health Issues
  • $105,000 Nov 16, 2022 Issue: Health Issues
  • $105,000 Aug 08, 2022 Issue: Health Issues
  • $20,000 Jul 20, 2022 Issue: Pharmacy
  • $105,000 Jun 09, 2022 Issue: Health Issues
  • $130,000 Apr 20, 2022 Issue: Pharmacy
  • $60,000 Jan 20, 2022 Issue: Health Issues
  • $130,000 Jan 20, 2022 Issue: Pharmacy
  • $60,000 Oct 21, 2021 Issue: Health Issues
  • $30,000 Oct 20, 2021 Issue: Pharmacy
  • $60,000 Jul 19, 2021 Issue: Health Issues
  • $60,000 Jul 19, 2021 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Method for use of a double-structured tissue implant for treatment of tissue May. 16, 2023
  • Patent Title: Cell and tissue culture container Jan. 17, 2023
  • Patent Title: Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders Aug. 25, 2020
  • Patent Title: Ophthalmic compositions and methods of use Feb. 11, 2020
  • Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Jan. 30, 2018
  • Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Mar. 21, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of OCGN in WallStreetBets Daily Discussion

OCGN News

Recent insights relating to OCGN

CNBC Recommendations

Recent picks made for OCGN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OCGN

Corporate Flights

Flights by private jets registered to OCGN